Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Vose, Julie M  [Clear All Filters]
2023
Stuver R, Horwitz SM, Advani RH, Vose JM, Lee HJu, Mehta-Shah N, Zain JM, Haverkos B, Lechowicz MJo, Moskowitz AJ, et al. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma. Br J Haematol. 2023.
Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Qureishi HNaushad, Link BK, et al. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium. J Hematol Oncol. 2023;16(1):122.
Vose JM, Ganguly S, Bierman PJ, R Bociek G, Lunning M, Lyden L, Meza JL, Caimi PF, Armitage JO. Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study. Br J Haematol. 2023.
2019
Kallam A, Vose JM. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma. Oncology (Williston Park). 2019;33(5).
2015
Vose JM. Mantle Cell Lymphoma: 2015 Update on Diagnosis, Risk-Stratification and Clinical Management. Am J Hematol. 2015.
2013
Vose JM. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2013;88(12):1082-8.